Difference between revisions of "Performance Based Pricing"
From Patient Determinants
| Line 1: | Line 1: | ||
| + | * [https://www.beckershospitalreview.com/supply-chain/novartis-cms-collaborate-on-outcomes-based-pricing-for-465k-leukemia-drug.html Novartis, CMS collaborate on outcomes-based pricing for $475k leukemia drug (8/31/17)] | ||
* [https://www.fiercehealthcare.com/analytics/patient-generated-data-could-be-missing-piece-to-new-payment-models-for-drugs-and-devices A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. (7/25/17)] | * [https://www.fiercehealthcare.com/analytics/patient-generated-data-could-be-missing-piece-to-new-payment-models-for-drugs-and-devices A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. (7/25/17)] | ||
* [https://healthpayerintelligence.com/news/amp/harvard-pilgrim-enters-outcomes-based-pharmaceutical-contracts Harvard Pilgrim Health Care has expanded its outcomes-based care contracts for certain pharmaceuticals by using outcomes as a metric for drug costs. (6/2/17)] | * [https://healthpayerintelligence.com/news/amp/harvard-pilgrim-enters-outcomes-based-pharmaceutical-contracts Harvard Pilgrim Health Care has expanded its outcomes-based care contracts for certain pharmaceuticals by using outcomes as a metric for drug costs. (6/2/17)] | ||
Latest revision as of 14:05, 16 July 2019
- Novartis, CMS collaborate on outcomes-based pricing for $475k leukemia drug (8/31/17)
- A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. (7/25/17)
- Harvard Pilgrim Health Care has expanded its outcomes-based care contracts for certain pharmaceuticals by using outcomes as a metric for drug costs. (6/2/17)
- Cigna, Novartis agree on outcome-based price for heart drug (2/9/16)
- Cigna first insurer to reach value-based agreements for new class of cholesterol drugs (5/12/16)
See Health Insurance Payment Models - Performance Based Pricing
